Profitability Ratios
| Ratio |
Value |
| GP Margin |
100.0% |
| EBIT Margin |
-1748.7% |
| EBITDA Margin |
-1566.1% |
| Operating Margin |
-1916.9% |
| Pretax Margin |
-1764.5% |
| Cont. Ops Margin |
-1764.5% |
| Net Margin |
-1764.5% |
| Bottom Line Margin |
-1764.5% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
1.27 |
| Quick Ratio |
1.27 |
| Solvency Ratio |
-0.522 |
| Cash Ratio |
0.77 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.21 |
| Forward PEG |
0.21 |
| Price/Book |
-6.14 |
| Price/Sales |
47.79 |
| Price/FCF |
-3.81 |
| Price/Op Cash Flow |
-4.09 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.3599 |
| Debt/Equity |
-1.0400 |
| Debt/Capital |
25.9758 |
| Long-Term Debt/Capital |
-1.7048 |
| Financial Leverage |
-2.89 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.09 |
| Operating Cash Flow Ratio |
-0.889 |
| Operating Cash Flow/Sales |
-1168.2% |
| Free Cash Flow/Operating Cash Flow |
107.2% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-4.87 |
| Interest Coverage |
-121.4205 |
| Short-Term Operating Cash Flow Coverage |
-3.82 |
| Operating Cash Flow Coverage |
-1.44 |
| Capital Expenditure Coverage |
-13.85 |
| Dividend + Capital Expenditure Coverage |
-13.85 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.03 |
| EPS |
-0.550 |
| Debt/Share |
0.2573 |
| Cash/Share |
0.38 |
| Book Value/Share |
-0.24 |
| Tangible BV/Share |
-0.24 |
| Equity/Share |
-0.24 |
| Operating Cash Flow/Share |
-0.364 |
| Capital Expenditure/Share |
0.026 |
| FCF/Share |
-0.390 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
0.920 |
| Price/Fair Value |
-6.14 |
| Debt/Market Cap |
0.1666 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-2.92 |
IPHA - Innate Pharma S.A.